ARTICLE SUMMARY:
BD’s recently announced $24-billion deal to buy CR Bard not only fills important technology gaps for BD and takes the company into new, higher-growth therapeutic device markets, it also enables BD to gain economic leverage through critical mass. In so doing, it is the latest mega-deal to advance a “post-technology vision” of the medtech market.
Size matters for medtech companies today, and Becton Dickinson Inc.’s (BD) recently announced $24-billion cash and stock mega-deal to acquire CR Bard is the latest case in point.
